MicroRNA-451 in chronic myeloid leukemia: MiR-451-BCR-ABL regulatory loop?

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 974-977

  Lopotová, Tereza ^a,b   Žáčková, Markéta ^a   Klamová, Hana ^a   Moravcová, Jana ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

BCR ABL kinase; Cell cultivation; CML; Imatinib; MiR 451; MiRNA

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MICRORNA;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; PRIORITY JOURNAL;

FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICRORNAS;

EID: 79958704585     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.03.029     Document Type: Article

References (8)

1. Agirre X., Jiménez-Velasco A., San José-Enériz E., et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res 2008, 6(12):1830-1840.
2. Calin G.A., Garzon R., Cimmino A., Fabbri M., Croce C.M. MicroRNAs and leukemias: how strong is the connection?. Leuk Res 2005, 30(6):653-655.
3. Pelosi E., Labbaye C., Testa U. MicroRNAs in normal and malinant myelopoiesis. Leuk Res 2009, 33(12):1584-1593.
4. Polakova K.M., Lopotova T., Klamova H., et al. Differential expression of miRNAs during the course of chronic myeloid leukemia (abstract). Blood 2008, 112(11):395-396.
5. ten Hoeve J., Arlinghaus R.B., Guo J.Q., Heisterkamp N., Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994, 84(6):1731-1736.
6. Cilloni D., Messa F., Gottardi E., et al. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004, 101(5):979-988.
7. Zackova M., Lopotova T., Ondrackova Z., et al. In vitro sensitivity to tyrosine kinase inhibitors is one of possible predictive parameters for therapy switch in patients with chronic myeloid leukemia (abstract). Blood 2010, 116(21):1133.
8. Iraci N., Valli E., Gherardi S., et al. Suppression of BCR-ABL expression in CML by a panel of miRNAs (abstract). Blood 2009, 114(22):351.